Baxter faces scrutiny over product defects amid CFO departure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2025
0mins
Should l Buy BAX?
Source: Globenewswire
Baxter International's stock has hit a 52-week low, reflecting ongoing concerns about the company's product quality and executive changes.
The recent investigation into Baxter's Novum LVP product, which is alleged to have systemic defects posing serious risks to patients, has raised significant concerns among investors. Additionally, the departure of CFO Joel Grade and the appointment of interim CFO Anita Zielinski has added to the uncertainty surrounding the company's financial management. Despite targeting an EPS of $1.85 to $2.05 for 2026, the challenges with flat organic sales continue to weigh on investor sentiment.
As Baxter navigates these challenges, the implications for its stock performance remain critical, especially in light of the broader market's positive movement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 18.710
Low
15.00
Averages
22.13
High
30.00
Current: 18.710
Low
15.00
Averages
22.13
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baxter Unveils Next-Gen Surgical Equipment at AORN
- Product Launch: Baxter showcased the AAT XR spine surgical table and Dynamo Series smart stretcher at the AORN Global Surgical Conference, aimed at enhancing surgical team efficiency and patient safety, with availability expected in the U.S. in the second half of 2026.
- Surgical Efficiency Improvement: The AAT XR is designed to rotate 180 degrees without removing the patient, featuring quick lock functions and a maximum weight capacity of 650 pounds, significantly reducing physical strain on operating room staff and optimizing surgical workflows.
- Smart Stretcher Innovation: The Dynamo Series smart stretcher addresses common challenges faced by care teams in high-pressure settings by reducing patient transfer needs and simplifying positioning, thereby lowering fall risks and improving patient comfort.
- Advanced Surgery Portfolio: Baxter also highlighted its extensive portfolio of hemostatic and sealing agents aimed at reducing bleeding-related complications and overall costs, further solidifying its market position in the surgical field.
See More
Baxter Launches IV Verify Line Labeling System to Enhance Patient Safety
- System Innovation: Baxter introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference, offering an automated alternative to traditional handwritten labels, aimed at enhancing medication management safety and efficiency while helping clinicians save time and reduce the likelihood of medication errors.
- Clinical Efficiency Boost: The IV Verify system allows clinicians to scan medication barcodes and instantly print three-part adhesive labels, saving an average of one to two minutes per IV setup, time that can be redirected to patient interactions, thereby improving the quality of care.
- Patient Safety Assurance: Implementation of the system has significantly increased IV labeling compliance in hospitals and reduced the incidence of central line-associated bloodstream infections (CLABSI) when used as part of a prevention bundle, highlighting its importance in high-risk environments.
- Broad Market Prospects: The launch of the IV Verify system reflects Baxter's ongoing commitment to advancing safe infusion practices, which is expected to drive growth in the company's market share within the healthcare technology sector, further solidifying its position as an innovation leader.
See More
Baxter's 2026 Annual Stockholders Meeting Details
- Meeting Format: Baxter International Inc. will host its Annual Stockholders Meeting virtually on May 5, 2026, starting at 9 a.m. Central Time, with online access beginning at 8:45 a.m., ensuring a safe and convenient experience for all stockholders and employees.
- Voting Arrangements: All stockholders are encouraged to vote their shares prior to the meeting using methods described in the proxy materials, while those who have not voted can do so electronically during the meeting, ensuring their voting rights are fully protected.
- Question Submission: Stockholders can submit questions both before and during the meeting, with pre-meeting questions accepted from April 21 to May 4, 2026, and live questions allowed during the meeting, ensuring timely responses to stockholder concerns.
- Guest Participation: Guests wishing to attend in listen-only mode can access the meeting via the website but will not have the ability to ask questions or vote, facilitating a smooth meeting process while still allowing stockholders to engage.
See More
Baxter Foundation's Major Investment in Therapy Animal Programs
- Partnership Announcement: The Baxter Foundation collaborates with Pet Partners to promote therapy animal programs in U.S. healthcare settings, aiming to reach 100,000 patients and healthcare professionals within two years, thereby enhancing healthcare system resilience.
- Pilot Program Launch: The initiative will begin in key regions such as Northern California, Upstate New York, and Greater Chicago, focusing on providing resources and training to help more healthcare facilities integrate animal therapy, addressing stress for healthcare workers and emotional challenges for patients.
- Therapeutic Benefits: Research indicates that therapy animals can significantly lower pain ratings and reduce anxiety and depression in patients, while even brief five-minute visits from therapy dogs have been shown to alleviate stress for healthcare workers, highlighting the healing power of the human-animal bond.
- Social Impact: This investment not only increases access to therapy animals but also enhances the mental health of healthcare workers and improves patient treatment experiences, demonstrating the Baxter Foundation's commitment to social responsibility.
See More
BAX vs CTRA Stock Performance Comparison
- Price Dynamics: BAX is currently trading down approximately 0.1%, indicating a cautious market sentiment that may impact investor confidence and lead to capital outflows.
- Strong CTRA Performance: In contrast, CTRA's stock is up about 3.3%, suggesting optimistic market expectations regarding its future growth potential, which may attract more investor interest.
- Market Sentiment Analysis: The slight decline in BAX juxtaposed with CTRA's rise highlights differing risk assessments and market confidence among investors, potentially influencing future investment decisions.
- Investor Focus: As the market compares the performances of BAX and CTRA, investors may reassess their portfolios to optimize returns and manage risks effectively.
See More
BAXTER - IFOSFAMIDE SUPPLY CONSTRAINTS EXPECTED TO GRADUALLY RESOLVE BY 2026
Limited Supply of IFOs: There is a restricted availability of IFOs (presumably a product or resource) currently affecting the market.
Gradual Improvement Expected: The situation is anticipated to improve gradually by the year 2026.
See More
Baxter Unveils Next-Gen Surgical Equipment at AORN
- Product Launch: Baxter showcased the AAT XR spine surgical table and Dynamo Series smart stretcher at the AORN Global Surgical Conference, aimed at enhancing surgical team efficiency and patient safety, with availability expected in the U.S. in the second half of 2026.
- Surgical Efficiency Improvement: The AAT XR is designed to rotate 180 degrees without removing the patient, featuring quick lock functions and a maximum weight capacity of 650 pounds, significantly reducing physical strain on operating room staff and optimizing surgical workflows.
- Smart Stretcher Innovation: The Dynamo Series smart stretcher addresses common challenges faced by care teams in high-pressure settings by reducing patient transfer needs and simplifying positioning, thereby lowering fall risks and improving patient comfort.
- Advanced Surgery Portfolio: Baxter also highlighted its extensive portfolio of hemostatic and sealing agents aimed at reducing bleeding-related complications and overall costs, further solidifying its market position in the surgical field.
See More
Baxter Launches IV Verify Line Labeling System to Enhance Patient Safety
- System Innovation: Baxter introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference, offering an automated alternative to traditional handwritten labels, aimed at enhancing medication management safety and efficiency while helping clinicians save time and reduce the likelihood of medication errors.
- Clinical Efficiency Boost: The IV Verify system allows clinicians to scan medication barcodes and instantly print three-part adhesive labels, saving an average of one to two minutes per IV setup, time that can be redirected to patient interactions, thereby improving the quality of care.
- Patient Safety Assurance: Implementation of the system has significantly increased IV labeling compliance in hospitals and reduced the incidence of central line-associated bloodstream infections (CLABSI) when used as part of a prevention bundle, highlighting its importance in high-risk environments.
- Broad Market Prospects: The launch of the IV Verify system reflects Baxter's ongoing commitment to advancing safe infusion practices, which is expected to drive growth in the company's market share within the healthcare technology sector, further solidifying its position as an innovation leader.
See More
Baxter's 2026 Annual Stockholders Meeting Details
- Meeting Format: Baxter International Inc. will host its Annual Stockholders Meeting virtually on May 5, 2026, starting at 9 a.m. Central Time, with online access beginning at 8:45 a.m., ensuring a safe and convenient experience for all stockholders and employees.
- Voting Arrangements: All stockholders are encouraged to vote their shares prior to the meeting using methods described in the proxy materials, while those who have not voted can do so electronically during the meeting, ensuring their voting rights are fully protected.
- Question Submission: Stockholders can submit questions both before and during the meeting, with pre-meeting questions accepted from April 21 to May 4, 2026, and live questions allowed during the meeting, ensuring timely responses to stockholder concerns.
- Guest Participation: Guests wishing to attend in listen-only mode can access the meeting via the website but will not have the ability to ask questions or vote, facilitating a smooth meeting process while still allowing stockholders to engage.
See More
Baxter Foundation's Major Investment in Therapy Animal Programs
- Partnership Announcement: The Baxter Foundation collaborates with Pet Partners to promote therapy animal programs in U.S. healthcare settings, aiming to reach 100,000 patients and healthcare professionals within two years, thereby enhancing healthcare system resilience.
- Pilot Program Launch: The initiative will begin in key regions such as Northern California, Upstate New York, and Greater Chicago, focusing on providing resources and training to help more healthcare facilities integrate animal therapy, addressing stress for healthcare workers and emotional challenges for patients.
- Therapeutic Benefits: Research indicates that therapy animals can significantly lower pain ratings and reduce anxiety and depression in patients, while even brief five-minute visits from therapy dogs have been shown to alleviate stress for healthcare workers, highlighting the healing power of the human-animal bond.
- Social Impact: This investment not only increases access to therapy animals but also enhances the mental health of healthcare workers and improves patient treatment experiences, demonstrating the Baxter Foundation's commitment to social responsibility.
See More
BAX vs CTRA Stock Performance Comparison
- Price Dynamics: BAX is currently trading down approximately 0.1%, indicating a cautious market sentiment that may impact investor confidence and lead to capital outflows.
- Strong CTRA Performance: In contrast, CTRA's stock is up about 3.3%, suggesting optimistic market expectations regarding its future growth potential, which may attract more investor interest.
- Market Sentiment Analysis: The slight decline in BAX juxtaposed with CTRA's rise highlights differing risk assessments and market confidence among investors, potentially influencing future investment decisions.
- Investor Focus: As the market compares the performances of BAX and CTRA, investors may reassess their portfolios to optimize returns and manage risks effectively.
See More
BAXTER - IFOSFAMIDE SUPPLY CONSTRAINTS EXPECTED TO GRADUALLY RESOLVE BY 2026
Limited Supply of IFOs: There is a restricted availability of IFOs (presumably a product or resource) currently affecting the market.
Gradual Improvement Expected: The situation is anticipated to improve gradually by the year 2026.
See More
